Related information about imported original research avatrombopag tablets/Su Kexin

Avatrombopag is a drug developed by a well-known international pharmaceutical company. It is mainly used to treat thrombocytopenia, especially in patients with immune thrombocytopenia (ITP) and chronic liver disease-related thrombocytopenia (CLD). Avatrombopag belongs to the thrombopoietin receptor agonist class of drugs. It works by stimulating the thrombopoietin receptor (TPO-R), thereby enhancing the bone marrow's ability to produce platelets.

In the treatment of primary immune thrombocytopenia (ITP), avatrombopag is used to increase platelet counts to reduce the patient's risk of bleeding. For patients with chronic liver disease-related thrombocytopenia (CLD), avatrombopag can increase platelet counts and provide patients with a safer surgical window, especially before undergoing invasive examinations or surgeries. Avatropopag can help reduce bleeding and improve surgical safety by increasing platelet counts.

The mechanism of action of avatrombopag is to simulate the effect of thrombopoietin (TPO), activate the thrombopoietin receptor, enhance the proliferation and differentiation of megakaryocytes, and thereby promote the production of platelets. Compared with other thrombopoietin receptor agonists, avatrombopag has higher selectivity and potency, and can significantly increase platelet counts in a short period of time and improve patients' clinical performance.

In the clinical application of avatrombopag, research results show that the drug is very effective in increasing platelet counts, especially in patients with immune thrombocytopenia and liver disease. Although the drug has significant efficacy in improving platelet counts, patients still need to have regular blood tests during use to monitor potential side effects, especially liver function and the risk of blood clots.

Overall, avatrombopag is an effective and safe drug with broad application prospects, especially in clinical settings where increasing platelet counts is required. As treatment experience continues to accumulate, it is expected to provide significant clinical benefits to more patients.

Reference materials:https://go.drugbank.com/drugs/DB11995